Cargando…

Cost-effectiveness evaluation of aspirin in primary prevention of myocardial infarction amongst males with average cardiovascular risk in Iran

Aspirin is one of the certified medicines commonly used for the secondary prevention of myocardial infarction (MI). Aspirin side effects and gastrointestinal bleeding, in particular, have arisen debates on its use for the primary prevention of MI. The present research evaluates the cost-effectivenes...

Descripción completa

Detalles Bibliográficos
Autores principales: Amirsadri, Mohammadreza, Sedighi, Mohammad Javad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5385729/
https://www.ncbi.nlm.nih.gov/pubmed/28515767
http://dx.doi.org/10.4103/1735-5362.202453
_version_ 1782520644310663168
author Amirsadri, Mohammadreza
Sedighi, Mohammad Javad
author_facet Amirsadri, Mohammadreza
Sedighi, Mohammad Javad
author_sort Amirsadri, Mohammadreza
collection PubMed
description Aspirin is one of the certified medicines commonly used for the secondary prevention of myocardial infarction (MI). Aspirin side effects and gastrointestinal bleeding, in particular, have arisen debates on its use for the primary prevention of MI. The present research evaluates the cost-effectiveness of the use of aspirin in the primary prevention of MI among Iranian men with average cardiovascular disease (CVD) risk, using Markov modeling technique. The incremental cost-effectiveness ratios (ICERs) estimated to be 864 USA dollars (USD) per quality-adjusted life years (QALY) gained and 782 USD per life years gained (LYG) for each patient in the base-case scenario (public tariffs and no discounting). This research proves cost-effectiveness of the use of aspirin in the primary prevention of MI in targeted population, since the assessed ICERs are quite under the recommended threshold by WHO which is one gross domestic product (GDP) per capita ($5315.1 for Iran in 2015).
format Online
Article
Text
id pubmed-5385729
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-53857292017-05-17 Cost-effectiveness evaluation of aspirin in primary prevention of myocardial infarction amongst males with average cardiovascular risk in Iran Amirsadri, Mohammadreza Sedighi, Mohammad Javad Res Pharm Sci Original Article Aspirin is one of the certified medicines commonly used for the secondary prevention of myocardial infarction (MI). Aspirin side effects and gastrointestinal bleeding, in particular, have arisen debates on its use for the primary prevention of MI. The present research evaluates the cost-effectiveness of the use of aspirin in the primary prevention of MI among Iranian men with average cardiovascular disease (CVD) risk, using Markov modeling technique. The incremental cost-effectiveness ratios (ICERs) estimated to be 864 USA dollars (USD) per quality-adjusted life years (QALY) gained and 782 USD per life years gained (LYG) for each patient in the base-case scenario (public tariffs and no discounting). This research proves cost-effectiveness of the use of aspirin in the primary prevention of MI in targeted population, since the assessed ICERs are quite under the recommended threshold by WHO which is one gross domestic product (GDP) per capita ($5315.1 for Iran in 2015). Medknow Publications & Media Pvt Ltd 2017-04 /pmc/articles/PMC5385729/ /pubmed/28515767 http://dx.doi.org/10.4103/1735-5362.202453 Text en Copyright: © 2017 Research in Pharmaceutical Sciences http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Original Article
Amirsadri, Mohammadreza
Sedighi, Mohammad Javad
Cost-effectiveness evaluation of aspirin in primary prevention of myocardial infarction amongst males with average cardiovascular risk in Iran
title Cost-effectiveness evaluation of aspirin in primary prevention of myocardial infarction amongst males with average cardiovascular risk in Iran
title_full Cost-effectiveness evaluation of aspirin in primary prevention of myocardial infarction amongst males with average cardiovascular risk in Iran
title_fullStr Cost-effectiveness evaluation of aspirin in primary prevention of myocardial infarction amongst males with average cardiovascular risk in Iran
title_full_unstemmed Cost-effectiveness evaluation of aspirin in primary prevention of myocardial infarction amongst males with average cardiovascular risk in Iran
title_short Cost-effectiveness evaluation of aspirin in primary prevention of myocardial infarction amongst males with average cardiovascular risk in Iran
title_sort cost-effectiveness evaluation of aspirin in primary prevention of myocardial infarction amongst males with average cardiovascular risk in iran
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5385729/
https://www.ncbi.nlm.nih.gov/pubmed/28515767
http://dx.doi.org/10.4103/1735-5362.202453
work_keys_str_mv AT amirsadrimohammadreza costeffectivenessevaluationofaspirininprimarypreventionofmyocardialinfarctionamongstmaleswithaveragecardiovascularriskiniran
AT sedighimohammadjavad costeffectivenessevaluationofaspirininprimarypreventionofmyocardialinfarctionamongstmaleswithaveragecardiovascularriskiniran